Filippo Ghelardi

Med Onc Fellow
📍New York, Milano

[samu💥 @foca_mon4ca]

non scherzo se vi dico che in questa foto non c’è UN (1) eterosessuale

[Filippo Ghelardi @FilippoGhelard]

Di discussioni, caroselli, eroi
Quel che è rimasto dimmelo un po’ tu

[Ultimora.net @ultimoranet]

Morto a 86 anni il cantautore Francesco Guccini

[Miley Official @MileyCyrusBz]

HANNAH MONTANA SINGING THE CLIMB. I AM SOBBING 🥺

[The BMJ @bmj_latest]

Gastro-oesophageal adenocarcinoma is a global challenge, ranking among the leading causes of cancer mortality.

This Editorial looks at the fundamental clinical question on how to balance treatment goals against sustainability
https://t.co/4mCzci9F2z

[Margherita Ambrosini @margheambro1]

In this review we go through the key aspects that characterize MSI-H/dMMR cancers, in light of recent diagnostic advances and the successes of immune checkpoint inhibitors in both advanced and early stage disease.

Have a look!

https://t.co/w1qvKYnwvI

[Filippo Ghelardi @FilippoGhelard]

@allthegods2 @Madonna Under educated retarded

[Filippo Ghelardi @FilippoGhelard]

@drizzyys Wait a damn second since when people don’t know Kendrick?????

[Filippo Ghelardi @FilippoGhelard]

@GwinLeanne @ReallyAmerican1 are you retarded ?

[Filippo Ghelardi @FilippoGhelard]

@charliekirk11

[Filippo Ghelardi @FilippoGhelard]

@dominiczaidan @daleethompson Not only will you see price increases, but also bear in mind you were promised prices cuts!

[Margherita Ambrosini @margheambro1]

Shorter ICI tx for dMMR/MSI-H mCRC isn't detrimental - may spare toxicities, costs and preserve QoL. Explore the findings from our study in @jitcancer & stay tuned for a future clinical trial on this question!

Thx to my mentors and all the contributors! 🇫🇷🇮🇹🇪🇸🇺🇸

[Ultimora.net @ultimoranet]

🔴 FLASH— LA GIORNALISTA CECILIA SALA ARRESTATA A TEHERAN, IRAN +++ @ultimoranet

[Filippo Ghelardi @FilippoGhelard]

@Annals_Oncology @giannatempopatr

[Filippo Ghelardi @FilippoGhelard]

@giubileif Giubilei sei proprio una poveretta

[Filippo Ghelardi @FilippoGhelard]

@curijoey @myESMO Congratulazioni professore!

[Filippo Ghelardi @FilippoGhelard]

Brilliant, solid, impeccable presentation at #ASCO24 by the one and only @FilippoPietran4. The road is still long and winding, but ARMANI is yet another step towards the optimisation of care for pts with gastric cancer. Congrats to all involved in this amazing academic effort.

[Massimo Di Maio @MassimoDiMaio75]

Brilliant presentation of the Italian ARMANI trial by @FilippoPietran4 at #ASCO24.
Bravo Filippo, as usual, and bravo to all investigators

[Margherita Ambrosini @margheambro1]

✨Excited and honored to can finally share our work about the rare and important subgroup of POLE/D1 proofreading deficient (pd) mCRC treated with ICIs across 🇪🇺🇺🇸🇮🇱

@FilippoPietran4 @paomanca @BenjcRousseau

@myESMO @Annals_Oncology

https://t.co/T1xboSKHIO

For details🧵⬇️

[AIOM @AIOMtweet]

Seconda edizione dell’ASCO-AIOM International Clinical Research Course: come sempre grande partecipazione ed entusiasmo.
#ASCO #AIOM @ASCO

[Kohei shitara @KoheiShitara]

KEYNOTE-585 is published @TheLancetOncol as presented at #ESMO24. Pembro+chemo improved pathCR of #gastriccancer but EFS was not statistically significant. MSI-H is distinguished population. Full results of Matterhorn awaited. @OncoAlert @myESMO @ASCO
https://t.co/AZrAItXLJV

[NEJM @NEJM]

Original Article: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C (CodeBreaK 300 phase 3 trial) https://t.co/mLuAayTmTM

#ESMO23 #oncology